AVXL EBITDA Growth
Anavex Life Sciences Corp · EBITDA Growth
AVXL EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported58.10%period ending
AVXL TTM EBITDA YoY % (81.35% → 58.10%)
Year-over-year change
High-resolution chart · PNG
AVXL ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 58.0983% | |
| 36.4333% | |
| 24.598% | |
| -0.4164% | |
| -15.5048% | |
| -22.7236% | |
| -22.2669% | |
| -0.1304% | |
| 10.5999% | |
| 17.9238% | |
| 15.263% | |
| 2.2787% | |
| -11.7231% | |
| -19.7001% | |
| -19.8632% | |
| -55.3104% | |
| -69.6522% | |
| -75.0031% | |
| -78.0721% | |
| 0.897% | |
| 10.4674% | |
| 14.3347% | |
| 19.7081% | |
| -7.395% | |
| -4.7637% | |
| -11.0178% | |
| -29.0927% | |
| -50.1626% | |
| -52.8557% | |
| -46.3828% | |
| -36.3269% | |
| -23.4572% | |
| -9.642% | |
| -13.6176% | |
| -17.1173% | |
| -4.4631% | |
| -23.6729% | |
| -19.9337% | |
| -20.911% | |
| -76.2913% | |
| -6.947% | |
| -5.4399% | |
| 6.2942% | |
| 25.732% | |
| -176.2006% | |
| -225.8971% | |
| -337.2969% | |
| -211.436% | |
| -284.8855% | |
| -103.9509% | |
| -10.509% | |
| 13.6247% | |
| 129.0434% | |
| 67.631% | |
| 62.4838% | |
| 31.1097% | |
| -25.6023% | |
| 13.4937% | |
| -8.6821% | |
| -13.8233% | |
| -31.3771% | |
| -27.3444% | |
| -47.7524% | |
| -13.7907% | |
| 7.0607% | |
| 3.2889% | |
| 18.7816% | |
| 11.3569% | |
| -48.3622% | |
| -75.3017% | |
| -105.9954% | |
| -238.5166% | |
| -756.4589% | |
| -1,486.0901% | |
| -8,848.9798% | |
| -6,063.895% | |
| -619.6643% | |
| -89.7813% | |
| 79.9899% | |
| 81.3522% |